10.06.2013 - British Alliance Pharma plc has bought the complete rights for Novartis’ obstetric drug Syntometrine.
The Chippenham-based specialty company already owns the UK rights to Syntometrine, an obstetric drug used in the final stage of labour. With the US$11.5m deal, Alliance Pharma adds Novartis’ assets in other countries to its portfolio.
The Novartis Group has been selling Syntometrine in Australia, South Africa, Malaysia and New Zealand. In the year from March 2012 to March 2013, the Swiss drug giant made US$3.2m in sales with Syntometrine; the gross margin generated was US$2.8m. Alliance Pharma estimates its annual distribution and operating costs associated with the new territories at US$780,000.
The British company, which generates annual sales of US$69.8m last year, will finance the deal from existing cash and bank facilities, including a US$5.4m drawdown from the group's US$40.7m acquisition facilities. This leaves US$15m of the facilities available to fund further acquisitions.
25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.
21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.
11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.